Immune Thrombocytopenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Immunomedics, Oscotech, Bioverativ, Novartis, Pfizer and Many Others

June 02 20:30 2021
Immune Thrombocytopenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Immunomedics, Oscotech, Bioverativ, Novartis, Pfizer and Many Others

Immune Thrombocytopenia Pipeline

Immune thrombocytopenia or ITP is a bleeding disorder. In ITP, the blood doesn’t clot as it should. This is due to a low number of blood cell fragments called platelets or thrombocytes. People who have ITP often have purple bruises called purpura. These bruises appear on the skin or mucous membranes. Bleeding from small blood vessels under the skin causes purpura. People who have ITP also may have bleeding that causes tiny red or purple dots on the skin. These pinpoint-sized dots are called petechiae. Petechiae may look like a rash.

DelveInsight’s, “Immune Thrombocytopenia Pipeline Insights, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Immune Thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 


Request for Free Sample Report:


Some of Immune Thrombocytopenia Companies are:

  • Argenx
  • HanAll Biopharma
  • Eris Lifesciences
  • Momenta Pharmaceuticals
  • Taiho Pharmaceutical
  • Takeda
  • UCB Pharma
  • Immunomedics
  • Oscotech
  • Bioverativ, a Sanofi company
  • Novartis
  • Pfizer
  • Kissei Pharmaceutical Co., Ltd.
  • And Many Others


Request for Free Sample Report:


DelveInsight’s Immune Thrombocytopenia report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Immune Thrombocytopenia Key Products

  • Efgartigimod
  • Rozanolixizumab
  • TAK-079
  • HL161
  • Romiplostim biosimilar
  • R788
  • M254
  • Eltrombopag
  • PRN1008
  • HMPL-523
  • SKI-O-703
  • HBM9161
  • BIVV009
  • And Many Others


Request for Free Sample Report:


Current Immune Thrombocytopenia Treatment Scenario and Immune Thrombocytopenia Emerging Therapies:

  • How many companies are developing Immune Thrombocytopenia drugs?
  • How many Immune Thrombocytopenia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune Thrombocytopenia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Immune Thrombocytopenia and their status?
  • What are the key designations that have been granted to the emerging drugs?


Table of Contents:


Executive Summary

Immune thrombocytopenia: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Immune thrombocytopenia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Immune thrombocytopenia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Immune thrombocytopenia Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Rozanolixizumab (UCB7665): UCB

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

BIVV-020: Bioverativ

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

• Comparative Analysis

M 254: Momenta Pharmaceuticals

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

• Comparative Analysis

CNP-105: Cour Pharmaceutical Development

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Immune thrombocytopenia Key Companies

Immune thrombocytopenia Key Products

Immune thrombocytopenia- Unmet Needs

Immune thrombocytopenia- Market Drivers and Barriers

Immune thrombocytopenia- Future Perspectives and Conclusion

Immune thrombocytopenia Analyst Views

Immune thrombocytopenia Key Companies


Request for Detailed TOC:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States